von Hippel-Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab.
Werner
W
Wackernagel
Eva-Maria
EM
Lackner
Stefan
S
Pilz
Christoph
C
Mayer
Vinzenz
V
Stepan
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D018325:Hemangioblastoma / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007275:Injections, Intravenous; D058990:Molecular Targeted Therapy; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000209:etiology; D055815:Young Adult; D006623:von Hippel-Lindau Disease / Q000150:complications*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab